VFA
LXRX icon

Virtus Fund Advisers’s Lexicon Pharmaceuticals LXRX Stock Holding History

Virtus Fund Advisers’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$939K Buy
+95,079
New +$988K 0.01% 301
2014
Q3 		– Sell
-2,786
Closed -$31K – 1579
2014
Q2 		$31K Buy
+2,786
New +$29.9K ﹤0.01% 2180

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $25.6B AUM 30.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

Virtus Fund Advisers's LXRX Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Lexicon Pharmaceuticals (LXRX) in Q4 2017: 95,079 shares worth $939K. The stake represents 0.01% of the portfolio and ranks #301 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in LXRX as recently as Q2 2014.

Virtus Fund Advisers first reported a position in LXRX in Q2 2014 and has held it in 2 quarters since. 133 funds tracked by Wall St. Rank hold LXRX as of Q4 2017.

  • Virtus Fund Advisers held 95,079 shares of Lexicon Pharmaceuticals worth $939K as of Q4 2017.
  • Lexicon Pharmaceuticals was a new Virtus Fund Advisers position in Q4 2017.
  • Lexicon Pharmaceuticals made up 0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #301 holding.
  • Virtus Fund Advisers first reported a position in Lexicon Pharmaceuticals in Q2 2014 and has held it in 2 quarters since.
  • 133 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.